Drug intelligence / Profile preview

fruquintinib + S-1

Development stage: Unknown
Lead developer: HUTCHMED
Modality: Small Molecules
Administration: Oral

Overview

Fruquintinib + S-1 is a combination therapy that pairs fruquintinib, a highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3, with S-1, an oral fluoropyrimidine anticancer agent. This combination leverages complementary mechanisms of action to enhance antitumor effects. Fruquintinib blocks new blood vessel growth associated with tumor proliferation, while S-1 provides cytotoxic effects. The combination has shown promising efficacy in various cancer types, particularly in advanced gastrointestinal cancers.

Brand names: S-1S1S 1
Other names: fruquintinib + S-1

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)

Beyond the preview

Go deeper on fruquintinib + S-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fruquintinib + S-1.

Explore the full profile